en · de · es · pt
analytical-notes.peptides4088.com › Blog › Background And Development History — Field Notes

Background And Development History — Field Notes

By Editorial Desk · published 2025-09-23 · last reviewed 2025-10-11 · Blog

hGH fragment comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.

Last reviewed on 2025-10-11. Where a claim depends on a specific study, the study is described rather than over-claimed.

Background and Development History

Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.

AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.

Identity And Research Background

AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.

AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.

Aod-9604 at a glance

PropertyValueNotes
Molecular classSynthetic peptideDerived from C-terminal region of human growth hormone
Approximate molecular massAbout 1.8 kDaVaries with sequence length and counterions
Confirmed receptor targetNone establishedNo confirmed growth hormone receptor agonism
Reported in vitro activityLipolysis stimulation and lipogenesis inhibitionObserved mainly in adipocyte models; human relevance uncertain
Regulatory statusNot approved as a drug in major marketsMay be treated differently across jurisdictions; not a recognized dietary ingredient in some countries

Regulatory and Analytical Context

In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.

Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.

Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.

Related pages on this site

Background And Research Context

In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.

AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.

The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.

Identity and Research Context

Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.

Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.

AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.

Identity and Research Origin

AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.

Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.

Notes from published material

The leader of the Libyan Islamist Fighting Group, Abdel-Hakim Belhaj, stated that while being tortured in Abu Salim prison, he was forced to give information regarding Libyans living in the United Kingdom, who were then allegedly arbitrarily arrested by the British government.

== Business activities == MacKinnon is co-inventor with his friend and scientific collaborator, neurobiologist Bruce Bean of Harvard Medical School, of a dietary supplement for treating and preventing muscle cramps; they tested it in clinical trials and are co-founders a company to commercialize their invention, Flex Pharma. Christoph Westphal and Jennifer Cermak were co-founders as well. The company undertook drug development of a formulation of supplement as a drug candidate for neuromuscular disorders like ALS, and raised a $40 million Series A round. The company had an $86 million initial public offering in 2015. In 2016, the company launched "HotShot" as a dietary supplement for endurance athletes. In June 2018 the company halted clinical development of the drug candidate due to tolerability issues, cut its workforce, and said it was considering its strategy. In July 2018 MacKinnon resigned from the board of directors.

==== Indolethylamine N-methyltransferase (INMT) ==== Before techniques of molecular biology were used to localize indolethylamine N-methyltransferase (INMT), characterization and localization went on a par: samples of the biological material where INMT is hypothesized to be active are subject to enzyme assay. Those enzyme assays are performed either with a radiolabeled methyl donor like (14C-CH3)SAM to which known amounts of unlabeled substrates like tryptamine are added or with addition of a radiolabeled substrate like (14C)NMT to demonstrate in vivo formation. As qualitative determination of the radioactively tagged product of the enzymatic reaction is sufficient to characterize INMT existence and activity (or lack of), analytical methods used in INMT assays are not required to be as sensitive as those needed to directly detect and quantify the minute amounts of endogenously formed DMT. The essentially qualitative method thin layer chromatography (TLC) was thus used in a vast majority of studies. Also, robust evidence that INMT can catalyze transmethylation of tryptamine into NMT and DMT could be provided with reverse isotope dilution analysis coupled to mass spectrometry for rabbit and human lung during the early 1970s. Selectivity rather than sensitivity proved to be a challenge for some TLC methods with the discovery in 1974-1975 that incubating rat blood cells or brain tissue with (14C-CH3)SAM and NMT as a substrate mostly yields tetrahydro-β-carboline derivatives, and negligible amounts of DMT in brain tissue.

Another difference between the older ACE inhibitors and RXP 407 is the molecular size of the compound. The older ACE inhibitors had mostly been interacting with S1’, S2’ and S1 subsites but RXP 407 interacts in addition with the S2 subsite. This also is important for the selectivity of the inhibitor since the aspartic side chain and N-acetyl group are located in the P2 position.

In the same month, The United Kingdom published its 10-year National AI Strategy, which states the British government "takes the long-term risk of non-aligned Artificial General Intelligence, and the unforeseeable changes that it would mean for ... the world, seriously". The strategy describes actions to assess long-term AI risks, including catastrophic risks. The British government held first major global summit on AI safety. This took place on the 1st and 2 November 2023 and was described as "an opportunity for policymakers and world leaders to consider the immediate and future risks of AI and how these risks can be mitigated via a globally coordinated approach". China Media Project stated "key aspects of its approach remain fundamentally unsafe by the standards of democratic societies worldwide", arguing that part of China's AI safety approach is focused on strengthening the Chinese Communist Party (CCP)'s information control. Government organizations, particularly in the United States, have also encouraged the development of technical AI safety research. The Intelligence Advanced Research Projects Activity initiated the TrojAI project to identify and protect against Trojan attacks on AI systems. The DARPA engages in research on explainable artificial intelligence and improving robustness against adversarial attacks. And the National Science Foundation supports the Center for Trustworthy Machine Learning, and is providing millions of dollars in funding for empirical AI safety research.

Sources: en.wikipedia.org

Background from the literature

Hydrolyzed vegetable protein (HVP) products are foodstuffs obtained by the hydrolysis of protein, and have a meaty, savory taste similar to broth (bouillon). Regarding the production process, a distinction can be made between acid-hydrolyzed vegetable protein (aHVP), enzymatically produced HVP, and other seasonings, e.g., fermented soy sauce. Hydrolyzed vegetable protein products are particularly used to round off the taste of soups, sauces, meat products, snacks, and other dishes, as well as for the production of ready-to-cook soups and bouillons.

X-ray scattering techniques are some of the most useful techniques for determining the structural identification and shape of lipids. An X-ray beam of light is applied to the lipid in which a distinct X-ray pattern is revealed. This lattice pattern is based on the electron density and localization of electrons dispersed throughout the lipid in order to determine atomic positions. The disadvantage is that it can be difficult to determine patterns in lipids that are not well oriented such as non-lamellar phases. Although this can be a limitation in producing electron density reconstructions in lipids, X-ray diffraction is still a reliable method for obtaining structural information and distinguishing between lamellar and non-lamellar phases.

In bacteria and organelles, the initiation of protein synthesis is signaled by the formation of formyl-methionyl-tRNA (tRNAfMet). This reaction is dependent on 10-formyltetrahydrofolate, and the enzyme methionyl-tRNA formyltransferase. This reaction is not used by eukaryotes or Archaea, as the presence of tRNAfMet in non bacterial cells is dubbed as intrusive material and quickly eliminated. After its production, tRNAfMet is delivered to the 30S subunit of the ribosome in order to start protein synthesis. fMet possesses the same codon sequence as methionine. However, fMet is only used for the initiation of protein synthesis and is thus found only at the N terminus of the protein. Methionine is used during the rest translation. In E. coli, tRNAfMet is specifically recognized by initiation factor IF-2, as the formyl group blocks peptide bond formation at the N-terminus of methionine. Once protein synthesis is accomplished, the formyl group on methionine can be removed by peptide deformylase. The methionine residue can be further removed by the enzyme methionine aminopeptidase.

==== Management of future flooding ==== The floodings from earlier in the year became an issue during the course of his reelection campaign in 2024. After he was questioned about the subject, Melo mentioned that "it will continue to flood". According to him, the situation would depend on drainage systems, but the budget did not cover projects to protect against flooding, and the new investment of $4.5 billion real would depend on the creation of a partnership with the Municipal Department of Water and Sewage (DMAE). During the same time period, strong rains affected the city, leaving the city without lights and transport, also affecting the swearing in of municipal secretaries, which had to be cancelled after the rain took out the lights. Former minister of president Lula da Silva, Paulo Pimenta, criticized Melo for his stance on the issue, claiming that he was responsible for the new bouts of flooding in Porto Alegre.

It is an optical analytical technique that analyzes the interference pattern of white light reflected from two surfaces: a layer of immobilized protein on the biosensor tip, and an internal reference layer. Any change in the number of molecules bound to the biosensor tip causes a shift in the interference pattern that can be measured in real-time, providing detailed information regarding the kinetics of association and dissociation of the two molecules as well as the affinity constant for the protein interaction (ka, kd and Kd). Due to sensor configuration, the technique is highly amenable to both purified and crude samples as well as high throughput screening experiments. The detection method can also be used to determine the molar concentration of analytes. Protein activity determination by NMR multi-nuclear relaxation measurements, or 2D-FT NMR spectroscopy in solutions, combined with nonlinear regression analysis of NMR relaxation or 2D-FT spectroscopy data sets. Whereas the concept of water activity is widely known and utilized in the applied biosciences, its complement—the protein activity which quantitates protein–protein interactions—is much less familiar to bioscientists as it is more difficult to determine in dilute solutions of proteins; protein activity is also much harder to determine for concentrated protein solutions when protein aggregation, not merely transient protein association, is often the dominant process.

Sources: en.wikipedia.org

Further detail

== Current issues == There are various usages of ethanol which include an additive to gasoline, a primary ingredient for food preservation as well as alcoholic beverages and being used for transdermal drug delivery. For example, it can function as an antiseptic in topical creams to kill bacteria by denaturing proteins. Ethanol is an amphiphilic molecule meaning that it has chemical and physical properties associated with hydrophobic and hydrophilic molecules. Although, studies show that when penetrating through the biomembrane its hydrophobic abilities appear to be limited based on its preference to bind closely to the hydrophilic region of the phospholipids. There are various issues presented in regards to ethanol's ability to penetrate through the biomembrane and cause a reorganization of the phospholipids towards non-lamellar phases. The issues are: 1) how the alteration of the phospholipids' phase occurs 2) understanding the significance of ethanol's interaction with membrane proteins and membrane phospholipids 3) understanding the permeability of the biomembrane based on the tolerance and adaptation level in the presence of ethanol although this process appears to be concentration-dependent 4) determining the significance of ethanol's amphiphilic character as it relates to its ability to partition throughout the membrane by increasing the fluidity of it. Ethanol's hydrophobic properties are limited and primarily binds close the hydrophilic region of the phospholipid.

The tidal chain reaction theory has mechanistic advantages over thermal association/dissociation at deep-sea vents because it requires that chain assembly (template-driven polymerization) takes place during the dry-down phase, when precursors are most concentrated, whereas thermal cycling needs polymerization to take place during the cold phase, when the rate of chain assembly is lowest and precursors are likely to be more dilute.

Higher pressure than CCC (typical operation pressures of 40–160 bar vs 5–25 bar) As the pressure drops on the LiLiChro's rotor with the new cells is less than 10bar, this disadvantage has been overcome by the technology and the all-new rotary union seals will last for years of continuous use. Rotary seal wear over time

Apart from several bog bodies, Denmark has also yielded several other mummies, such as the three Borum Eshøj mummies, the Skrydstrup Woman and the Egtved Girl, who were all found inside burial mounds, or tumuli. In 1875, the Borum Eshøj grave mound was uncovered, which had been built around three coffins, which belonged to a middle aged man and woman as well as a man in his early twenties. Through examination, the woman was discovered to be around 50–60 years old. She was found with several artifacts made of bronze, consisting of buttons, a belt plate, and rings, showing she was of higher class. All of the hair had been removed from the skull later when farmers had dug through the casket. Her original hairstyle is unknown. The two men wore kilts, and the younger man wore a sheath which contained a bronze dagger. All three mummies were dated to 1351–1345 BC. The Skrydstrup Woman was unearthed from a tumulus in Southern Jutland, in 1935. Carbon-14 dating showed that she had died around 1300 BC; examination also revealed that she was around 18–19 years old at the time of death, and that she had been buried in the summertime. Her hair had been drawn up in an elaborate hairstyle, which was then covered by a horse hair hairnet made by the sprang technique. She was wearing a blouse and a necklace as well as two golden earrings, showing she was of higher class. The Egtved Girl, dated to 1370 BC, was also found inside a sealed coffin within a tumulus, in 1921. She was wearing a bodice and a skirt, including a belt and bronze bracelets.

=== Fatty acids and insulin secretion === Fatty acids also affect insulin secretion. In type 2 diabetes, fatty acids are able to potentiate insulin release to compensate the increment need of insulin. It was found that the β-cells express free fatty acid receptors at their surface, through which fatty acids can impact the function of β-cells. Long-chain acyl-CoA and DAG are the metabolites resulting from the intracellular metabolism of fatty acids. Long-chain acyl-CoA has the ability to acylate proteins that are essential in the insulin granule fusion. On the other hand, DAG activates PKC that is involved in the insulin secretion.

Sources: en.wikipedia.org

Frequently asked questions

What is AOD9604 derived from?

AOD9604 is a synthetic peptide based on a C-terminal segment of human growth hormone. It is manufactured by chemical peptide synthesis rather than extracted from human tissue. The sequence is often described as hGH fragment 176–191 or a close variant.

Is AOD9604 approved as a medicine?

It is not approved as a prescription drug in the United States or the European Union for any indication. Regulatory status can differ by country, and it is often sold as a research chemical or in unapproved products. Such products are not equivalent to an approved medicine.

Does AOD9604 raise IGF-1 levels?

In the studies reported so far, AOD9604 does not appear to act through the growth hormone receptor and has not shown the typical IGF-1 increase caused by full-length hGH. Human data are limited, so this remains an area of uncertainty. It should not be assumed to have the same effects as hGH.

Is AOD-9604 the same as human growth hormone?

No. It is a synthetic peptide fragment modeled on part of human growth hormone, not the full hormone. It does not contain the complete sequence or receptor-binding regions of hGH.

Network